Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Shabnam Naseer

Showing results (1-10 of 2) with videos related to

Pageof 1
Sort By:
Clinical Pharmacology and Therapeutics|July 6, 2022
Cefiderocol Dosing for Patients Receiving Continuous Renal Replacement TherapyXiaohui Wei, Shabnam Naseer, Edward A Weinstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 4, 2021
US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®)Shabnam Naseer, Edward A Weinstein, Daniel B Rubin, et al.
Pageof 1

Showing results (1-10 of 2) with videos related to

Sort By:
Pageof 1
Clinical Pharmacology and Therapeutics|July 6, 2022
Cefiderocol Dosing for Patients Receiving Continuous Renal Replacement TherapyXiaohui Wei, Shabnam Naseer, Edward A Weinstein, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 4, 2021
US Food and Drug Administration (FDA): Benefit-Risk Considerations for Cefiderocol (Fetroja®)Shabnam Naseer, Edward A Weinstein, Daniel B Rubin, et al.
Pageof 1